Bristol-Myers Squibb Co., of New York, Eisai Co. Ltd., of Tokyo, and its Cambridge, Mass.-based precision medicine research & development subsidiary H3 Biomedicine Inc., said they have entered into a multi-year research collaboration focused on evaluating whether novel therapeutics leveraging H3's RNA splicing platform can provide a more powerful response against cancer.